NIBR-LTSi dihydrochloride is a highly selective and orally available LATS kinase inhibitor with an IC50 value of 1.4 nM. NIBR-LTSi activates YAP signaling, shows good oral bioavailability, and expands organoids derived from several mouse and human tissues. In tissue stem cells, NIBR-LTSi promotes proliferation, maintains stemness, and blocks differentiation in vitro and in vivo.

KEYWORDS: NIBR-LTSi dihydrochloride | Supplier | LATS inhibitor | NIBRLTSi | NIBR LTSi | CAS [N.A.] | YAP/Hippo pathway | LATS | Inhibitor | Transcription Factors | Liver regeneration | Hyperplasia